VALEANT Pharmaceuticals
subsidiary, Biovail Laboratories, has
entered into an agreement to acquire
Australian pharmacy skincare
brands Hamilton’s Suncare and
Hamilton’s Skin Therapy.
Currently ranked in the number
two spot for suncare products in
the Aussie pharmacy market,
Hamilton’s annual sales round out
at around AU$10 million.
Valeant expects the acquisition
to gradually add to its earnings per
share in 2010.
“These leading skin care brands
nicely augment Valeant’s current
suncare product portfolio and
expands our presence in the
pharmacy over-the-counter (OTC)
market,” said Valeant ceo Michael
Pearson.
“The brands we acquired
through our previous transactions
have continued to perform well
and the addition of a key brand
such as Hamilton Sunscreen will
enhance our portfolio and offer
synergies to our growing pharmacy
OTC platform,” he added.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Nov 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Nov 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.